Why do sglt2 inhibitors cause euglycemic dka

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: SGLT2 inhibitors cause euglycemic diabetic ketoacidosis (DKA) primarily by promoting glucosuria and ketogenesis while suppressing insulin secretion. This occurs because these drugs block renal glucose reabsorption, leading to urinary glucose excretion of 60-80 grams per day, which depletes glycogen stores and shifts metabolism toward fat breakdown. Concurrently, reduced insulin levels due to lower blood glucose trigger lipolysis and ketone production, with cases typically presenting at blood glucose levels below 250 mg/dL (normal DKA threshold is >250 mg/dL). First reported in 2015 with canagliflozin, the FDA issued a safety warning in May 2015 after identifying 73 cases.

Key Facts

SGLT2 inhibitors cause urinary glucose excretion of 60-80 grams per day
Euglycemic DKA typically presents with blood glucose levels below 250 mg/dL
First cases reported in 2015 with canagliflozin
FDA issued safety warning in May 2015 after identifying 73 cases
Risk factors include reduced food intake, illness, surgery, or insulin dose reduction

Overview

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a class of oral antidiabetic medications first approved by the FDA in 2013 with canagliflozin (Invokana), followed by dapagliflozin (Farxiga) in 2014 and empagliflozin (Jardiance) in 2014. These drugs work by inhibiting SGLT2 proteins in the proximal renal tubules, preventing approximately 90% of glucose reabsorption and promoting glucosuria. While effective for glycemic control in type 2 diabetes, they were associated with an unexpected complication: euglycemic diabetic ketoacidosis (euDKA), where patients develop DKA with normal or mildly elevated blood glucose levels. Traditional DKA typically presents with hyperglycemia (>250 mg/dL), but euDKA cases often show glucose levels between 100-250 mg/dL. The first published reports emerged in 2015, prompting regulatory attention. By 2020, post-marketing surveillance had identified hundreds of cases globally, leading to updated prescribing guidelines and black box warnings in some countries.

How It Works

The mechanism involves three interconnected pathways: First, SGLT2 inhibition causes significant glucosuria (60-80 g/day), depleting hepatic glycogen stores within 24-48 hours and reducing glucose availability. Second, this glucosuria lowers blood glucose levels, which paradoxically decreases insulin secretion from pancreatic beta cells by approximately 30-50% in susceptible individuals. Third, the reduced insulin levels (along with increased glucagon) activate hormone-sensitive lipase, accelerating lipolysis and releasing free fatty acids into circulation. These fatty acids undergo beta-oxidation in liver mitochondria, producing acetyl-CoA that exceeds citric acid cycle capacity, leading to ketogenesis and accumulation of beta-hydroxybutyrate and acetoacetate. Normally, insulin suppresses ketogenesis, but with SGLT2 inhibitors, this suppression is inadequate despite euglycemia. Additional triggers like dehydration, illness, or reduced carbohydrate intake exacerbate this process by further lowering insulin and increasing counterregulatory hormones.

Why It Matters

Euglycemic DKA matters clinically because it presents diagnostic challenges—healthcare providers may miss DKA due to normal glucose readings, delaying treatment. Studies show diagnosis is delayed by 12-48 hours in 60% of cases, increasing morbidity. It affects approximately 0.1-0.5% of SGLT2 inhibitor users, with higher risk in type 1 diabetes (off-label use) and during perioperative periods. Recognition has changed clinical practice: guidelines now recommend discontinuing SGLT2 inhibitors 3-4 days before surgery and monitoring ketones during illness. The FDA warning has improved patient education about symptoms like nausea, vomiting, and fatigue. From a drug safety perspective, this adverse effect highlights the importance of post-marketing surveillance, as it wasn't detected in pre-approval trials involving over 10,000 patients.